Modern therapy of young and adult Ph-ALL.

Leukemia supplements Pub Date : 2012-08-01 Epub Date: 2012-08-09 DOI:10.1038/leusup.2012.6
R Bassan, T Intermesoli, O Spinelli, E Oldani, A Rambaldi
{"title":"Modern therapy of young and adult Ph-ALL.","authors":"R Bassan,&nbsp;T Intermesoli,&nbsp;O Spinelli,&nbsp;E Oldani,&nbsp;A Rambaldi","doi":"10.1038/leusup.2012.6","DOIUrl":null,"url":null,"abstract":"<p><p>Acute lymphoblastic leukemia (ALL) in adults is currently associated with an overall survival rate of around 40% at 5 years. This is an unsatisfactory result that makes it imperative to dissect further the biology of the disease in order to identify highly specific therapeutic targets to implement selectively the cure rate. The recognition of discrete ALL subsets followed by the application of risk-oriented therapies has been a major achievement over the past 30 years. </p>","PeriodicalId":91571,"journal":{"name":"Leukemia supplements","volume":"1 Suppl 2","pages":"S5-6"},"PeriodicalIF":0.0000,"publicationDate":"2012-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1038/leusup.2012.6","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia supplements","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/leusup.2012.6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2012/8/9 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Acute lymphoblastic leukemia (ALL) in adults is currently associated with an overall survival rate of around 40% at 5 years. This is an unsatisfactory result that makes it imperative to dissect further the biology of the disease in order to identify highly specific therapeutic targets to implement selectively the cure rate. The recognition of discrete ALL subsets followed by the application of risk-oriented therapies has been a major achievement over the past 30 years.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
青年和成人Ph-ALL的现代治疗。
成人急性淋巴细胞白血病(ALL)目前的5年总生存率约为40%。这是一个令人不满意的结果,这使得有必要进一步解剖疾病的生物学,以确定高度特异性的治疗靶点,以选择性地实施治愈率。在过去的30年里,识别离散的ALL亚群并应用风险导向疗法是一项重大成就。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Abstracts from the 2nd International Norges Teknisk-Naturvitenskapelige Universitet (NTNU) Symposium: Day 1—Immunotherapy and Hematology Altered microenvironmental regulation of CML stem cells. Harnessing alloreactivity to achieve anti-leukemic responses. Reconsidering marrow stem cell cycle status: insights into an actively cycling hematopoietic stem cell population. Targeting leukemia stem cells with HDAC inhibitors and modulators of the DNA damage response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1